Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Isovorin · 2 trials · 2 indications
| Name | Type | Description |
|---|---|---|
| Isovorin | DRUG | - |
| UFT | DRUG | - |
| TS-1 | DRUG | - |
Inclusion Criteria: * Dukes C, Cure A colon cancer diagnosed histologically or cytologically * Normal organ function of bone marrow, heart, liver and kidney * Age 20-75 Other inclusion applies Exclusion Criteria: * Serious bone marrow suppression, infection, heart disease or complication * Famil...
Isovorin is an investigational small molecule being studied for the treatment of gastric cancer and colon cancer. It is developed by Pfizer, Inc. (NYSE: PFE) and is currently in Phase 3 clinical development for these oncology indications.
Isovorin is developed by Pfizer, Inc., a biopharmaceutical company traded on the New York Stock Exchange under the ticker symbol PFE. The drug is being investigated for use in gastric cancer and colon cancer.
Isovorin is in Phase 3 clinical development. It is an investigational drug, meaning it has not been approved by regulatory authorities and is still being studied in clinical trials for the treatment of gastric cancer and colon cancer.
Isovorin has been studied in two completed Phase 3 trials. NCT00195572 evaluated Isovorin in advanced or recurrent gastric cancer with 200 participants in Japan. NCT00195585 evaluated Isovorin in colon cancer with 650 participants in Japan. Both trials enrolled adults aged 20 years and older.
Isovorin is a form of folinic acid, also known as leucovorin. It is a small molecule used as a rescue agent in cancer chemotherapy. The drug is being developed by Pfizer, Inc. for the treatment of gastric and colon cancers.